Patents by Inventor Guido Grandi

Guido Grandi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11066453
    Abstract: The present invention provides means and products for the stimulation of an immune response against tumors in a subject in need thereof. More specifically the invention provides immunogenic compositions containing bacterial outer membrane vesicles loaded with tumor antigens, fusion proteins comprising a bacterial protein and a tumor antigen, and isolated bacterial outer membrane vesicles (OMVs) containing said fusion proteins. The fusion proteins, OMVs and immunogenic compositions according to the invention are used in the prevention and treatment of tumors.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: July 20, 2021
    Assignee: BIOMVIS SRL
    Inventors: Guido Grandi, Valeria Cafardi, Laura Fantappieā€², Renata Grifantini, Alberto Grandi
  • Patent number: 11027004
    Abstract: This invention relates to outer membrane vesicles (OMVs) from Gram-negative bacteria. The vesicles comprise heterologous proteins or immunogenic fragments thereof expressed as lipoproteins in their membrane. The OMVs of the invention are capable of eliciting an immune response to the heterologous protein or to a fragment thereof when administered to a mammal. Other aspects of the invention relate to methods of preparing the OMVs and immunogenic compositions containing the same.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: June 8, 2021
    Assignee: BIOMVIS SRL
    Inventors: Guido Grandi, Laura Fantappie', Carmela Irene
  • Patent number: 10716842
    Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CTI 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: July 21, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Guido Grandi, Renata Maria Grifantini, Oretta Finco
  • Patent number: 10428121
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 1, 2019
    Assignees: Novartis AG, J. Craig Venter Institute, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • Publication number: 20190282685
    Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CTI 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.
    Type: Application
    Filed: January 29, 2019
    Publication date: September 19, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Guido GRANDI, Renata Maria GRIFANTINI, Oretta FINCO
  • Patent number: 10336794
    Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: July 2, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Jeannette Adu-Bobie, Mariagrazia Pizza, Nathalie Norais, Germano Ferrari, Guido Grandi
  • Patent number: 10286055
    Abstract: Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from Streptococcus agalactiae (GBS) serotypes conjugated to carrier proteins.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 14, 2019
    Assignee: GlaxosmithKline Biologicals SA
    Inventors: Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
  • Patent number: 10245310
    Abstract: The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a BP-2a antigen and a spb1 antigen. BP-2a and spb1 are Streptococcus agalactiae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: April 2, 2019
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Francesco Berti, Roberta Cozzi, Domenico Maione, Cira Daniela Rinaudo, Immaculada Margarit Y Ros, Guido Grandi
  • Patent number: 10195263
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: February 5, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Fabio Bagnoli, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
  • Publication number: 20180353587
    Abstract: The present invention provides means and products for the stimulation of an immune response against tumors in a subject in need thereof. More specifically the invention provides immunogenic compositions containing bacterial outer membrane vesicles loaded with tumor antigens, fusion proteins comprising a bacterial protein and a tumor antigen, and isolated bacterial outer membrane vesicles (OMVs) containing said fusion proteins. The fusion proteins, OMVs and immunogenic compositions according to the invention are used in the prevention and treatment of tumors.
    Type: Application
    Filed: May 17, 2016
    Publication date: December 13, 2018
    Applicant: UNIVERSITA' DEGLI STUDI DI TRENTO
    Inventors: Guido Grandi, Valeria Cafardi, Laura Fantappie', Renata Grifantini, Alberto Grandi
  • Patent number: 10086060
    Abstract: The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS).
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: October 2, 2018
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Guido Grandi, Domenico Maione, Cira Daniela Rinaudo
  • Publication number: 20180207255
    Abstract: This invention relates to outer membrane vesicles (OMVs) from Gram-negative bacteria. The vesicles comprise heterologous proteins or immunogenic fragments thereof expressed as lipoproteins in their membrane. The OMVs of the invention are capable of eliciting an immune response to the heterologous protein or to a fragment thereof when administered to a mammal. Other aspects of the invention relate to methods of preparing the OMVs and immunogenic compositions containing the same.
    Type: Application
    Filed: October 23, 2017
    Publication date: July 26, 2018
    Applicant: UNIVERSITA' DEGLI STUDI DI TRENTO
    Inventors: Guido Grandi, Laura Fantappie', Carmela Irene
  • Patent number: 9987345
    Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 5, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Renata Maria Grifantini, Oretta Finco, Erika Bartolini, Guido Grandi
  • Publication number: 20180104324
    Abstract: Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from Streptococcus agalactiae (GBS) serotypes conjugated to carrier proteins.
    Type: Application
    Filed: November 21, 2017
    Publication date: April 19, 2018
    Applicant: GLAXOSMITHKLIINE BIOLOGICALS SA
    Inventors: Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
  • Publication number: 20180094033
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Application
    Filed: November 7, 2017
    Publication date: April 5, 2018
    Inventors: John TELFORD, Vega MASIGNANI, Maria SCARSELLI, Guido GRANDI, Herve TETTELIN, Claire FRASER
  • Publication number: 20180092970
    Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.
    Type: Application
    Filed: May 9, 2017
    Publication date: April 5, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Guido GRANDI, Renata Maria GRIFANTINI, Oretta FINCO
  • Patent number: 9926344
    Abstract: Elimination of disulphide bond formation of cysteine-containing S. aureus antigens enhances antigen stability. The invention provides variant forms of cysteine-containing S. aureus antigen with a point mutation that replaces, deletes or modifies the cysteine residue.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: March 27, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Fabio Bagnoli, Fabiana Falugi, Guido Grandi, Massimo Mariani, Mikkel Nissum, Michele Pallaoro, Silvana Savino
  • Publication number: 20180036402
    Abstract: A method of immunization against Group B Streptococcus infection, using an immunogenic composition conjugates of GBS capsular saccharide conjugated to carrier proteins.
    Type: Application
    Filed: September 15, 2017
    Publication date: February 8, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco BERTI, Mario CONTORNI, Paolo COSTANTINO, Oretta FINCO, Guido GRANDI, Domenico MAIONE, John TELFORD
  • Publication number: 20180009852
    Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.
    Type: Application
    Filed: September 7, 2017
    Publication date: January 11, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Jeannette ADU-BOBIE, Mariagrazia PIZZA, Nathalie NORAIS, Germano FERRARI, Guido Grandi
  • Patent number: 9855325
    Abstract: The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype Ia conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype Ib conjugated to a carrier protein; c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein; d) a conjugate that is a capsular saccharide from GBS serotype II conjugated to a carrier protein; and e) a conjugate that is a capsular saccharide from GBS serotype V conjugated to a carrier protein.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: January 2, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione